Ghent University Academic Bibliography

Advanced

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis

Philippe Gevaert UGent, NICHOLAS VAN BRUAENE UGent, Tom Cattaert UGent, Kristel Van Steen UGent, Thibaut Van Zele UGent, Frederic Acke UGent, Natalie De Ruyck UGent, Katrien Blomme UGent, Anna Sousa and Richard Marshall, et al. (2011) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 128(5). p.989-995
abstract
Background: Approximately 85% of nasal polyps (NPs) in white subjects are characterized by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival. Objective: We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal polyposis. Methods: Thirty patients with severe nasal polyposis (grade 3 or 4 or recurrent after surgery) refractory to corticosteroid therapy were randomized in a double-blindfashion to receive either 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (n = 20) or placebo (n = 10). Change from baseline in NP score was assessed monthly until 1 month after the last dose (week 8). Computed tomographic scans were also performed at week 8. Results: Twelve of 20 patients receiving mepolizumab had a significantly improved NP score and computed tomographic scan score compared with 1 of 10 patients receiving placebo at week 8 versus baseline. Conclusion: Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
mepolizumab, Anti-IL-5, eosinophils, chronic rhinosinusitis, nasal polyposis, HYPEREOSINOPHILIC SYNDROME, CHRONIC RHINOSINUSITIS, ANTI-INTERLEUKIN-5 ANTIBODY, INFLAMMATION, EXPRESSION, DISEASE, INTERLEUKIN-5, EOSINOPHILIA, SINUSITIS, SCH55700
journal title
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
J. Allergy Clin. Immunol.
volume
128
issue
5
pages
989 - 995
Web of Science type
Article
Web of Science id
000296578200011
JCR category
ALLERGY
JCR impact factor
11.003 (2011)
JCR rank
1/23 (2011)
JCR quartile
1 (2011)
ISSN
0091-6749
DOI
10.1016/j.jaci.2011.07.056
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2034412
handle
http://hdl.handle.net/1854/LU-2034412
date created
2012-02-15 20:00:27
date last changed
2012-03-14 12:46:22
@article{2034412,
  abstract     = {Background: Approximately 85\% of nasal polyps (NPs) in white subjects are characterized by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival. 
Objective: We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal polyposis. 
Methods: Thirty patients with severe nasal polyposis (grade 3 or 4 or recurrent after surgery) refractory to corticosteroid therapy were randomized in a double-blindfashion to receive either 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (n = 20) or placebo (n = 10). Change from baseline in NP score was assessed monthly until 1 month after the last dose (week 8). Computed tomographic scans were also performed at week 8. 
Results: Twelve of 20 patients receiving mepolizumab had a significantly improved NP score and computed tomographic scan score compared with 1 of 10 patients receiving placebo at week 8 versus baseline. 
Conclusion: Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.},
  author       = {Gevaert, Philippe and VAN BRUAENE, NICHOLAS and Cattaert, Tom and Van Steen, Kristel and Van Zele, Thibaut and Acke, Frederic and De Ruyck, Natalie and Blomme, Katrien and Sousa, Anna and Marshall, Richard and Bachert, Claus},
  issn         = {0091-6749},
  journal      = {JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY},
  keyword      = {mepolizumab,Anti-IL-5,eosinophils,chronic rhinosinusitis,nasal polyposis,HYPEREOSINOPHILIC SYNDROME,CHRONIC RHINOSINUSITIS,ANTI-INTERLEUKIN-5 ANTIBODY,INFLAMMATION,EXPRESSION,DISEASE,INTERLEUKIN-5,EOSINOPHILIA,SINUSITIS,SCH55700},
  language     = {eng},
  number       = {5},
  pages        = {989--995},
  title        = {Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis},
  url          = {http://dx.doi.org/10.1016/j.jaci.2011.07.056},
  volume       = {128},
  year         = {2011},
}

Chicago
Gevaert, Philippe, NICHOLAS VAN BRUAENE, Tom Cattaert, Kristel Van Steen, Thibaut Van Zele, Frederic Acke, Natalie De Ruyck, et al. 2011. “Mepolizumab, a Humanized anti-IL-5 mAb, as a Treatment Option for Severe Nasal Polyposis.” Journal of Allergy and Clinical Immunology 128 (5): 989–995.
APA
Gevaert, P., VAN BRUAENE, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., et al. (2011). Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 128(5), 989–995.
Vancouver
1.
Gevaert P, VAN BRUAENE N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2011;128(5):989–95.
MLA
Gevaert, Philippe, NICHOLAS VAN BRUAENE, Tom Cattaert, et al. “Mepolizumab, a Humanized anti-IL-5 mAb, as a Treatment Option for Severe Nasal Polyposis.” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 128.5 (2011): 989–995. Print.